title: Prognostic factors of acute non lymphoblastic leukemia in children and adults. Results from two multicentric trials (705 patients).
abstract: 705 children and adults patients with de novo acute nonlymphoblastic leukemia were entered from 1981 to 1989 into 2 prospectives multicenter trials: 01AM81 and 01AM86. They received an intensive induction course with Rubidazone 200 mg/sqm/day x 4 days and cytosine arabinoside 200 mg/sqm/day x 7 days, then 3 consolidation courses at outpatients, and a maintenance treatment. Total duration of therapy was 3 years. The overall complete remission rate was 80%. The median overall survival time was 19 months and the 5-year survival rate is 26%. The median remission duration for the 568 remitters was 18 months and the 5-year first remission rate is 30%. Prognostic factors for the remission rate were age, initial leukocytosis, FAB subtype. Prognostic factors for remission duration were the delay until CR, initial leukocytosis and karyotype.
authors.affiliation: Department of Hematology, Hôpital Saint-Louis, Paris, France.
authors.forename: S
authors.initials: S
authors.lastname: Castaigne
authors.forename: S
authors.initials: S
authors.lastname: Chevret
authors.forename: E
authors.initials: E
authors.lastname: Lepage
authors.forename: F
authors.initials: F
authors.lastname: Guilhot
authors.forename: P
authors.initials: P
authors.lastname: Fenaux
authors.forename: D
authors.initials: D
authors.lastname: Bordessoule
authors.forename: H
authors.initials: H
authors.lastname: Tilly
authors.forename: G
authors.initials: G
authors.lastname: Auzanneau
authors.forename: G
authors.initials: G
authors.lastname: Tertian
authors.forename: H
authors.initials: H
authors.lastname: Guy
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D006801:Humans; D007223:Infant; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000401:mortality; D008875:Middle Aged; D011379:Prognosis; D011446:Prospective Studies; D012074:Remission Induction / Q000379:methods; D015996:Survival Rate